Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (pli…
Stem cells derived from amniotic membrane can benefit retinal diseases when transplanted
Tests on animal models show that MSCs secrete growth factors that suppress causes of diabetic retinopathy and macular degenerationA team of researchers in South Korea has successfully…
Adjunct oxygen therapy helps improve corneal edema after cataract surgery
Transcorneal oxygen therapy as an adjunct to conventional therapy for severe corneal edema following cataract surgery preserved more endothelial cells and decreased corneal edema faster than conventional therapy alone or conventional therapy plus systemic oxygen, according to a study.Forty-five patients with central corneal thickness of more than 1,000 µm at day 1 postoperatively were divided into three equal groups: a control group receiving conventional medical therapy, a group receiving medical therapy plus systemic normobaric 100% oxygen by facemask and a group receiving medical therapy and transcorneal 100% oxygen. Oxygen therapy continued for 3 weeks, and no oxygen-related complications were observed.
Research and Markets: Blepharitis Pipeline Review, H2 2015 – Reviews Key Players Involved in the Therapeutics Development for Blepharitis
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/j28ndw/blepharitis) has announced the addition of the “Blepharitis – Pipeline Review, H2 2015” report to their offering. Summary This report provides comprehensiv…
InSite reports $6.6 million net loss in second quarter
InSite Vision reported a net loss of $6.6 million, or $0.05 per share, in the second quarter compared with a net income of $37.1 million, or $0.28 per share, in the same quarter of 2014, according to a press release.The 2014 income was attributed to a …
Part-time patching shows no benefit in treating intermittent exotropia
Part-time patching was shown to be no more effective than observation among children between the ages of 12 months and 35 months with intermittent exotropia, according to a study.The randomized, multicenter clinical trial included 201 children with int…